David G. Washburn - Concepedia

Author

David G. Washburn

GlaxoSmithKline (United States)

Also Known As

D. G. WASHBURN, D. Washburn, D.G. Washburn, David G Washburn, David G. Washburn, David Washburn, David washburn

Publications

404

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation University of North Carolina at Chapel Hill New Frontier South College

About

David G. Washburn is an author at GlaxoSmithKline (United States) specializing in pharmacology, drug discovery, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	157
2	Biochemistry	5	5	164
3	Engineering	2	2	50
4	Natural Sciences	2	2	80
5	Biomolecular Engineering	1	1	37

David G. Washburn

Publications

379

Citations

H-Index

Page 1

	Year	Citations
Asymmetric Total Synthesis of Spongistatins 1 and 2 Michael T. Crimmins, Jason D. Katz, David G. Washburn, Journal of the American Chemical Society	2002	94
The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore David G. Washburn, Dennis A. Holt, Jason W. Dodson, Bioorganic & Medicinal Chemistry Letters Signal TransductionBiochemistryAnilino-thiazole PharmacophoreMedicineFunctional Selectivity	2013	58
Concise Formal Synthesis of (−)-Peduncularine via Ring-Closing Metathesis David G. Washburn, Richard W. Heidebrecht, Stephen F. Martin Organic Letters	2003	57
Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors Marlys Hammond, David G. Washburn, Tram H. Hoang, Bioorganic & Medicinal Chemistry Letters Bioavailable SerumMedicinal ChemistryPharmaceutical ScienceBiochemistryMedicine	2009	43
Synthesis of the AB spiroketal subunit of spongistatin 1 (altohyrtin A): The Pyrone approach Michael T. Crimmins, David G. Washburn Tetrahedron Letters BiosynthesisBioorganic ChemistryEngineeringBiochemistrySpongistatin 1	1998	37
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1 Lara S. Kallander, David G. Washburn, Mark A. Hilfiker, ACS Medicinal Chemistry Letters	2018	21
Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists Scott K. Thompson, David G. Washburn, James S. Frazee, Bioorganic & Medicinal Chemistry Letters Hormonal ContraceptiveRational DesignMedicineHormonal ReceptorPharmacological Agent	2009	18
Synthesis and SAR of potent LXR agonists containing an indole pharmacophore David G. Washburn, Tram H. Hoang, Nino Campobasso, Bioorganic & Medicinal Chemistry Letters Pharmaceutical ScienceBiochemistryMedicinePharmacological AgentPharmacotherapy	2009	16
Addition of metalated pyrones to β-alkoxy aldehydes: Synthesis of hydroxylated spiroketals Michael T. Crimmins, David G. Washburn, Jason D. Katz, Tetrahedron Letters Chemical EngineeringEngineeringMetalated PyronesOrganic ChemistryCatalysis	1998	13
Improving the developability profile of pyrrolidine progesterone receptor partial agonists Lara S. Kallander, David G. Washburn, Tram H. Hoang, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyHormonal ContraceptiveMedicineHormonal ReceptorPhysiology	2009	12

Page 1